文献速递心力衰竭与心肌病瓣膜病与结构性心脏病

Acoramidis对转甲状腺素蛋白淀粉样心肌病全因死亡与心血管住院的疗效

Efficacy of Acoramidis on All-Cause Mortality and Cardiovascular Hospitalization in Transthyretin Amyloid Cardiomyopathy.
PubMed 文献 · J Am Coll Cardiol · 2025-01-01

ATTRibute-CM 3期随机双盲试验纳入632例ATTR-CM患者,按2:1接受acoramidis 800 mg每日两次或安慰剂治疗30个月。在改良意向治疗人群(611例)中,acoramidis较安慰剂降低全因死亡或首次心血管住院复合终点(35.9% vs 50.5%,HR 0.64,95%CI 0.50-0.83,P=0.0008)及首次心血管住院风险,且耐受性良好。

要点

  • acoramidis降低全因死亡或首次心血管住院复合终点风险达36%。
  • acoramidis降低首次心血管住院风险40%,年化住院频率减半。
  • 疗效在亚组间一致,Kaplan-Meier曲线自第3个月分离并持续至30个月。

核心结论

  • 在ATTR-CM患者中,acoramidis较安慰剂降低全因死亡或首次心血管住院复合终点及首次心血管住院风险,早期效应由心血管住院减少驱动。

研究设计与样本

  • ATTRibute-CM为3期随机双盲试验,632例ATTR-CM患者按2:1随机接受acoramidis 800 mg每日两次或安慰剂治疗30个月。
  • 疗效分析纳入改良意向治疗人群(基线eGFR≥30 mL/min/1.73 m2)共611例(acoramidis 409例,安慰剂202例)。

主要发现

  • acoramidis组全因死亡或首次心血管住院复合终点发生率为35.9%,安慰剂组为50.5%(HR 0.64,95%CI 0.50-0.83,P=0.0008)。
  • acoramidis组首次心血管住院发生率为26.7%,安慰剂组为42.6%(HR 0.60,95%CI 0.45-0.80,P=0.0005)。
  • acoramidis组心血管住院年化频率为0.22,安慰剂组为0.45(相对风险比50%,95%CI 0.36-0.70,P<0.0001)。
  • Kaplan-Meier曲线自第3个月分离并持续至第30个月,复合终点疗效在各亚组间一致。
  • acoramidis耐受性良好,未发现潜在临床关注的安全性信号。

临床怎么用

  • 对于ATTR-CM患者,acoramidis 800 mg每日两次可考虑用于降低全因死亡或心血管住院复合风险及心血管住院频率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Transthyretin amyloid cardiomyopathy (ATTR-CM) is an underdiagnosed chronic disease associated with progressive heart failure that results in impaired quality of life, repeated hospitalizations, and premature death. Acoramidis is a selective, oral transthyretin stabilizer recently approved by the U.S. Food and Drug Administration for the treatment of ATTR-CM. In a phase 3, randomized, double-blind study (ATTRibute-CM [Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy]), acoramidis was well tolerated and showed clinical efficacy in improving the primary endpoint, a hierarchical combination of all-cause mortality (ACM), cardiovascular-related hospitalization (CVH), N-terminal pro-B-type natriuretic peptide level, and 6-minute walk distance. OBJECTIVES: The goal of this study was to characterize the efficacy of acoramidis on ACM and CVH. METHODS: In ATTRibute-CM, participants with ATTR-CM were randomized 2:1 to receive acoramidis hydrochloride (800 mg twice daily) or placebo for 30 months. Efficacy analyses were conducted in the modified intention-to-treat population (participants with a baseline estimated glomerular filtration rate ≥30 mL/min/1.73 m2). CVH and the composite of ACM or first CVH were plotted by using Kaplan-Meier curves and summarized with a stratified Cox proportional hazards model. The annualized frequency of CVH was analyzed by using a negative binomial regression model. Subgroup analyses were conducted for the composite of ACM or first CVH. RESULTS: Of the 632 participants randomized to treatment, 611 (97%) were included in efficacy analyses (acoramidis, n = 409; placebo, n = 202). Compared with placebo, acoramidis reduced the occurrence of the composite of ACM or first CVH (acoramidis, 35.9%; placebo, 50.5%; HR: 0.64; 95% CI: 0.50-0.83; P = 0.0008) and of first CVH (acoramidis, 26.7%; placebo, 42.6%; HR: 0.60; 95% CI: 0.45-0.80; P = 0.0005), with Kaplan-Meier curves separating at month 3 and continuing to diverge through month 30. Annualized frequency of CVH was reduced with acoramidis compared with placebo (acoramidis, 0.22; placebo, 0.45; relative risk ratio: 50%; 95% CI: 0.36-0.70; P < 0.0001). The efficacy of acoramidis on the composite of ACM or first CVH was consistent across subgroups. Acoramidis was well tolerated, with no safety signals of potential clinical concern identified. CONCLUSIONS: In participants with ATTR-CM, acoramidis reduced the composite of ACM or first CVH vs placebo, with an early effect driven by a reduction in CVH. (Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy [ATTRibute-CM]; NCT03860935).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Judge DP, Alexander KM, Cappelli F, et al. Efficacy of Acoramidis on All-Cause Mortality and Cardiovascular Hospitalization in Transthyretin Amyloid Cardiomyopathy. J Am Coll Cardiol. 2025. PMID: 40074465. doi:10.1016/j.jacc.2024.11.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。